Erratum: Overall survival and durable responses in patients with braf v600–mutant metastatic melanoma receiving dabrafenib combined with trametinib (Journal of Clinical Oncology (2016) 34 (871-878) DOI: 10.1200/JCO.2015.62.9345);Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib

Journal of Clinical Oncology

Volumn 34, Issue 8, 2016, Pages 871-878

  Long, Georgina V ^a   Weber, Jeffrey S ^f   Infante, Jeffrey R ^g   Kim, Kevin B ^h   Daud, Adil ⁱ   Gonzalez, Rene ^k   Sosman, Jeffrey A ^m   Hamid, Omid ^j   Schuchter, Lynn ⁿ   Cebon, Jonathan ^e   Kefford, Richard F ^a,b,c,d   Lawrence, Donald ^q   Kudchadkar, Ragini ^f   Burris, Howard A ^g   Falchook, Gerald S ^l   Algazi, Alain ⁱ   Lewis, Karl ^k   Puzanov, Igor ^m   Ibrahim, Nageatte ^o   Sun, Peng ^p   Cunningham, Elizabeth ^o   Kline, Amy S ^p   Del Buono, Heather ^p   McDowell, Diane Opatt ^p   Patel, Kiran ^q   Flaherty, Keith T ^r   more..

^a MELANOMA INSTITUTE AUSTRALIA   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

^e AUSTIN HEALTH   (Australia)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g SARAH CANNON RESEARCH INSTITUTE   (United States)

^h CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j Angeles Clinic and Research Institute   (United States)

^k UNIVERSITY OF COLORADO   (United States)

^l HealthOne   (United States)

^m VANDERBILT UNIVERSITY   (United States)

ⁿ UNIVERSITY OF PENNSYLVANIA   (United States)

^o MERCK RESEARCH LABORATORIES   (United States)

^p GLAXOSMITHKLINE   (United States)

^q Experimental Station   (United States)

^r MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; IPILIMUMAB; LACTATE DEHYDROGENASE; TRAMETINIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; OXIME; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FEVER; GENE MUTATION; HUMAN; HYPONATREMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SKIN CARCINOMA; TREATMENT RESPONSE; CLINICAL TRIAL; ENZYMOLOGY; GENETICS; MELANOMA; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; IMIDAZOLES; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; SURVIVAL RATE;

EID: 84962486398     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.18.02267     Document Type: Erratum

References (28)

1. Flaherty KT, Robert C, Hersey P, et al; METRIC Study Group: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107-114, 2012
2. Chapman PB, Hauschild A, Robert C, et al: Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. J Clin Oncol 30, 2012 (abstr 8502)
3. Hauschild A, Grob JJ, Demidov LV, et al: Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365, 2012
4. Flaherty KT, Infante JR, Daud A, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694-1703, 2012
5. Long GV, Stroyakovskiy D, Gogas H, et al: Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371:1877-1888, 2014
6. Robert C, Karaszewska B, Schachter J, et al: Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372:30-39, 2015
7. Larkin J, Ascierto PA, Dréno B, et al: Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371:1867-1876, 2014
8. 7a. Robert C, Karaszewska B, Schackter J, et al: Two-year estimate of overall survival in COMBI-v, a randomized, open-label, phase 3 study comparing the combination of dabrafenib and trametinib vs vemurafenib as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. Eur J Canc 51, 2015(suppl 3)
9. Schadendorf D, Hodi FS, Robert C, et al: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. Eur J Cancer 49, 2013(suppl 3; abstr 24)
10. Topalian SL, Sznol M, McDermott DF, et al: Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020-1030, 2014
11. Robert C, Long GV, Brady B, et al: Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320-330, 2015
12. Hamid O, Robert C, Daud A, et al: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134-144, 2013
13. 11a. Robert C, Schachter J, Long GV, et al: Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521-2532, 2015
14. 11b. Larkin J, Chiarion-Sileni V, Gonzalez R, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23-34, 2015
15. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
16. Balch CM, Gershenwald JE, Soong SJ, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-6206, 2009
17. Hauschild A, Grobb J, Demidov L, et al: An update on overall survival (OS) and follow-on therapies in BREAK-3, a phase III, randomized trial: Dabrafenib (D) vs. dacarbazine (DTIC) in patients (pts) with BRAF V600E mutation-positive metastatic melanoma (MM). Ann Oncol 25:iv374-iv393, 2014 (abstr)
18. McArthur GA, Chapman PB, Robert C, et al: Safety and efficacy of vemurafenib in BRAF (V600E) and BRAF (V600K) mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15:323-332, 2014
19. Joseph RW, Elassaiss-Schaap J, Wolchok JD, et al: Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol 32, 2014 (abstr 3015)
20. Kelderman S, Heemskerk B, Van Tinteren H, et al: Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 63:449-458, 2014
21. Long GV, Fung C, Menzies AM, et al: Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAFmutant metastatic melanoma. Nat Commun 5:5694, 2014
22. Moriceau G, Hugo W, Hong A, et al: Tunablecombinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell 27:240-256, 2015
23. Wagle N, Van Allen EM, Treacy DJ, et al: MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov 4:61-68, 2014
24. Rizos H, Menzies AM, Pupo GM, et al: BRAF inhibitor resistance mechanisms in metastatic melanoma: Spectrum and clinical impact. Clin Cancer Res 20:1965-1977, 2014
25. Shi H, Hugo W, Kong X, et al: Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 4:80-93, 2014
26. Van Allen EM, Wagle N, Sucker A, et al; Dermatologic Cooperative Oncology Group of Germany (DeCOG): The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 4:94-109, 2014
27. Ribas A, Hodi FS, Kefford R, et al: Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J Clin Oncol 32, 2014 (abstr LBA9000)
28. 24a. Menzies AM, Wilmott JS, Drummond M, et al: Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer 121:3826-3835, 2015